Loading clinical trials...
Loading clinical trials...
Phase II Study of CIMAVAX-EGF in Combination With KRAS G12C Inhibitors as Treatment for Advanced Stage KRAS G12C Mutated NSCLC
Conditions
Interventions
Adagrasib
Biospecimen Collection
+4 more
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
June 1, 2026
Primary Completion Date
June 1, 2029
Completion Date
June 1, 2029
Last Updated
April 21, 2026
NCT07288034
NCT06660407
NCT06500455
NCT05198830
NCT03191149
NCT06122064
Lead Sponsor
Roswell Park Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions